BRCA2 (BReast CAncer susceptibility gene 2) germline mutation carriers are at increased risk for breast and ovarian cancers. Mutations occurring in the ovarian cancer cluster region (OCCR) are linked to higher ovarian cancer and/or lower breast cancer risk(s) than mutations occurring elsewhere in BRCA2. Most BRCA2 germline mutations introduce premature termination codons (PTCs), making their mRNAs likely targets of nonsense-mediated mRNA decay (NMD), a mechanism that eliminates PTC-bearing transcripts to prevent expression of truncated proteins. Contradictory evidence exists regarding whether NMD can be triggered by PTCs located far upstream of the nearest exon-exon junction (EEJ). Since the OCCR comprises a major portion of the 4.9 kb exon 11 of BRCA2, we investigated if transcripts bearing PTCs in this large exon are unable to trigger NMD, and if this might contribute to the phenotypic difference associated with the OCCR. We examined cDNA from 18 carriers of PTC-introducing germline mutations located throughout BRCA2, and found that PTC-bearing transcripts were 1.4-3.3-fold less prevalent than their nonmutated counterparts irregardless of PTC position. We conclude that NMD can recognize PTCs up to 4.5 kb upstream of the nearest EEJ, demonstrating that a general inability of NMD to recognize PTCs in exon 11 is unlikely to explain the genotype-phenotype correlation associated with the OCCR. Keywords: BRCA2; ovarian cancer cluster region; nonsense-mediated mRNA decay; genotype-phenotype correlation Germline mutations in the BRCA1 (BReast CAncer susceptibility gene 1) and BRCA2 genes account for a significant fraction of familial breast cancer and ovarian cancer cases (Thompson and Easton, 2004) . The BRCA2 gene, similar to BRCA1, appears to function as a tumour suppressor or cellular 'caretaker' and encodes a 3418-amino-acid protein that participates in the maintenance of genomic stability through its involvement in the DNA double-strand break repair process (reviewed in Venkitaraman, 2002; Yoshida and Miki, 2004) . Evidence indicates that BRCA2 participates directly in the repair process via its interaction with RAD51, a central enzyme in the DNA double-strand break repair pathway (Mizuta et al., 1997; Wong et al., 1997; Chen et al., 1998) .
The vast majority of documented deleterious mutations in BRCA2 introduce a premature termination codon (PTC) into the open-reading frame (Breast Cancer Information Core database; http://research.nhgri. nih.gov/bic/). As a result, transcripts generated from most mutant BRCA2 alleles are expected to be targeted by nonsense-mediated mRNA decay (NMD), a cellular mechanism that eliminates PTC-containing (PTC þ ) mRNAs to prevent the synthesis of potentially detrimental truncated proteins. In mammals, NMD distinguishes normal termination codons from PTCs on the basis of their location relative to exon-exon junctions (EEJs). During a pioneering round of translation, the positions of EEJs are indicated by the presence of the exon-junction complex (EJC), a multiprotein complex deposited approximately 20-24 nucleotides (nt) upstream of exon-exon boundaries during the process of mRNA splicing. Transcripts bearing termination codons >50 nt upstream of the last EEJ are considered premature and targeted for degradation, while those with termination codons located o50 nt from the last EEJ or lacking a downstream EEJ (i.e. termination codon occurs in the last exon) avoid detection (reviewed in Maquat, 2004) .
The BRCA2 transcript possesses a 10.2 kb coding sequence spread over 27 exons, including the exceptionally large (4.9 kb) exon 11. In 1997, Gayther et al. (1997) reported that mutations occurring within a 3.3 kb region of BRCA2 exon 11 were linked to an increased lifetime risk of developing ovarian cancer relative to breast cancer as compared to mutations occurring outside of these bounds. This region, named the ovarian cancer cluster region (OCCR), was later refined to roughly encompass the region bounded by nucleotides 3035-6629 (Thompson and Easton, 2001; Lubinski et al., 2004) . Although the biological mechanism behind this genotype-phenotype variation is unknown, the presence of the RAD51-binding BRC repeats within the OCCR has led to speculation that the expression of C-terminally truncated BRCA2 possessing at least one BRC repeat may be involved (Thompson and Easton, 2001 ). However, since most germline BRCA2 mutations introduce PTCs, this hypothesis conflicts with current models of NMD that predict PTC þ transcripts will be eliminated to prevent the production of truncated BRCA2.
Interestingly, a PTC located 559 nt upstream of the EEJ in the trisephosphate isomerase (TPI) gene was reported to escape NMD detection (Zhang et al., 1998) . The loosely defined limits of the OCCR place the 3 0 boundary approximately 441 nt upstream of the exon 11-12 boundary. Therefore, we theorized that if BRCA2 follows the NMD pattern of the TPI gene, then PTCs within the OCCR might be special in that they avoid detection by the NMD pathway and result in the production of BRC-containing truncated proteins. By contrast, transcripts bearing a PTC in smaller exons or within B500 nt of the exon 11-12 boundary would be targeted by NMD, thus undermining the expression of truncated proteins.
In this study we have examined whether PTCs located in the 4.9 kb exon 11 of BRCA2, and particularly those residing in the OCCR, are recognized by NMD. To address this issue, we compared the relative abundance of transcripts with PTCs in exon 11 to those harbouring PTCs in smaller exons. In all, 14 different PTC þ BRCA2 transcripts from the lymphoblastoid cell lines of 18 BRCA2 germline mutation carriers were examined.
Determination of differences in allele-specific transcript abundance: We have developed a novel technique to detect differences in allele-specific transcript abundance that is based on the SimpleProbe s genotyping analysis assay from Roche Diagnostics (Mannheim, Germany). In this method (see Supplementary Information), singly labelled, fluorescent oligonucleotide probes were designed to anneal to the sequence surrounding a singlenucleotide polymorphism (SNP), with complete complementarity to one variant while mismatching the other variant at the polymorphic position. This technique allows the two alleles in heterozygous individuals to be distinguished by differences in melting temperature (T m ), with the probe dissociating from the mismatching template at a lower temperature. The presence and relative abundance of each allelic template is determined by performing melting-curve analysis, where changes in the fluorescence properties of the probe as it dissociates from the two allelic templates are monitored as the probe/template duplexes are slowly raised in temperature. For this study, we designed probes for two frequent SNPs in BRCA2, one located in the 5 0 -untranslated region (5 0 UTR) of exon 2 (203A/G) and the other in exon 10 (N372H). It should be noted that two individuals in this study were homozygous for both of these SNPs (Table 1) . We therefore analysed these samples via single-nucleotide primer extension, a technique that has previously been used to measure variations in the expression levels of allele-specific transcripts in both humans (Yan et al., 2002) and mice (Cowles et al., 2002) . The distance to the next closest downstream EEJ is included in brackets since the PTC is o50 nt from closest EEJ.
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We began our study by establishing that SimpleProbe s melting-curve analysis could detect changes in the relative abundance of two DNA templates differing in a single nucleotide by assessing the heights of the peaks at the corresponding melting temperatures for each variant. As shown in Figure 1a , melting-curve analysis performed on varying mixtures of two PCR amplicons differing at the 5 0 UTR SNP (203A/G) revealed that differences in the abundance of each amplicon are easily visualized by examining peak heights. Next, we proceeded to examine the peak heights ratio for the two BRCA2 alleles in genomic DNA from a large collection of known heterozygotes. Despite the fact that the copy number of each allele is theoretically equal, we noted that the peak height ratio was not 1:1. The mean value of the common variant over that of the rare variant was 1.2270.06 and 0.7370.1 for the 5 0 UTR (203A/G) and N372H probes, respectively (data not shown). The low standard deviation we observed for our genomic DNA samples demonstrated that this assay is very reproducible, thus allowing us to use these values to normalize our peak height ratios when calculating relative transcript abundance levels for our cDNA samples.
We continued our assessment of SimpleProbe s melting-curve analysis by examining if transcripts expressed from two wild-type BRCA2 alleles were present at approximately the same levels in control individuals with no BRCA2 germline mutations. We examined cDNA from 14 control individuals using either the 5 0 UTR (203A/G) or N372H probes. As expected, the relative abundance of each allele-specific transcript corresponded closely to a 1:1 ratio, with the least abundant transcript species present at 79-99% of the level of the most abundant (Figure 1b) . This variation between the two wild-type alleles is within the range previously observed in other human genes (Yan et al., 2002) .
Effect of NMD on different PTC-bearing BRCA2 transcripts: To assess whether the location of the PTC within BRCA2 affected the ability of NMD to target PTC þ transcripts for destruction, we selected 18 lymphoblastoid cell lines harbouring 14 different PTC-introducing germline mutations to examine in this study (Table 1) . Samples were chosen to include mutations that introduced PTCs throughout the openreading frame, with eight of the 14 PTCs occurring in exon 11 ( Figure 2 ). As shown in Figure 3 , all samples with PTC-introducing mutations demonstrated obvious differences in transcript expression for the two BRCA2 alleles, with the least abundant transcript species ranging from 30 to 71% of the level of the most abundant species. Cosegregation analysis (or direct observation of the mutation by single-nucleotide primer extension) determined that, in 11 out of 18 of these samples, the least abundant allele carried the PTC-introducing mutation. The mutation-carrying allele for the remaining seven samples could not be assessed. Treatment of the cell lines with puromycin, a potent inhibitor of translation often used to inhibit NMD, prior to harvesting the total RNA resulted in 0 UTR (203A/G) SNP located in BRCA2 exon 2. PCR products generated from genomic DNA extracted from individuals homozygous for either the common (A) or rare (G) variant using the PUREGENE s DNA Purification kit (Gentra Systems Inc., Minneapolis, MN, USA) were mixed in the following ratios (A:G): 5:1, 3:1, 2:1, 1:1, 1:2, 1:3 and 1:5 for use as template DNA in melting-curve analysis. The location of the peaks corresponding to the common (A) and rare (G) variant products is indicated. (b) Relative abundance of the two wild-type BRCA2 alleles in noncarriers. Samples were assayed by melting-curve analysis using either the 5 0 UTR (black bars) or N372H (grey bars) probes. Peak height ratios were calculated, and then normalized by dividing the observed ratio by that obtained for a panel of genomic DNA (gDNA) samples. The least prevalent allele is expressed as a percentage of the most prevalent. Each bar on the graph represents the mean value of at least four independent measurements. Figure 2 Schematic representation of BRCA2 transcript indicating the relative position in nucleotides of the premature termination codons (PTCs) examined in this study. A PTC arising from a deletion of exon 7 is inaccurately represented on the same diagram to alleviate complexity of the figure and is noted in brackets. The mutation not leading to a PTC is boxed. The boundaries of the OCCR reported by Thompson and Easton (2001) are shown as light grey boxes. Functional domains including BRC repeats 1-8, oligonucleotide-binding (OB) domains 1-3, the helical domain (HD) and the nuclear localization sequences (NLS) are specified. significant elevation in the expression of the less abundant transcript species, in most cases to levels nearing those of the unaffected allele. This observation further supports the notion that NMD was responsible for the reduced transcript levels. In contrast to these observations, an individual harbouring a mutation that deletes only the codon for asparagine 1599 (del1599Asp) and should not trigger NMD, as well as eight control samples (shown as the mean value of all eight samples combined) exhibited very similar transcript expression levels with and without puromycin treatment (Figure 3) .
When possible, multiple individuals with the same mutation were analysed in order to compare their relative transcript abundance. Two mutations (ter275 and ter1284) were examined in two individuals from the same family and two mutations (ter2098 and ter2337) were examined in two unrelated individuals (Table 1) . In all cases, the results both with and without puromycin treatment were very consistent (Figure 3) .
Five of our study samples were heterozygous for both common BRCA2 SNPs, permitting the independent examination of transcript expression levels in the same cDNA sample using independent probes centred on our two chosen SNPs. In each case, melting-curve analysis with either probe gave very consistent results, thus further demonstrating the reliability of our study technique (Figure 4) .
We have measured the relative abundance of allelespecific transcripts in lymphoblastoid cell lines from 18 BRCA2-truncating mutations carriers, harbouring mutations located throughout the open-reading frame. We have observed that all of the examined samples exhibited observable differences in the relative abundance of their allele-specific BRCA2 transcripts, with the less prevalent transcript species present at 30-71% of the level of the more abundant form. This translates to Relative Transcript Abundance   0%   20%   40%   60%   80%   100%   120% 140% t e r 1 9 0 t e r 2 4 0 t e r 2 7 5 t e r 2 7 5 t e r 7 7 1 T r p 9 9 3 t e r t e r 1 2 5 8 t e r 1 2 8 4 t e r 1 2 8 4 S e r 1 8 8 2 t e r t e r 1 9 0 7 t e r 1 9 0 9 t e r 2 0 9 8 t e r 2 0 9 8 t e r 2 3 3 7 t e r 2 3 3 7 S e r 2 6 7 0 t e r t e r 2 9 7 5 d e l 1 5 9 9 A s n C o n t r o l Untreated Puromycin * ‡ ‡ * ‡ Figure 3 Relative abundance of BRCA2 allele-specific transcripts in lymphoblastoid cell lines established from carriers and noncarriers of germline BRCA2 mutations. Total RNA was extracted using the Total RNA Isolation kit (Macherey-Nagel SARL, Hoerdt, France). cDNA were obtained by random priming with the SuperScriptt III Reverse Transcriptase (Invitrogen SARL, Cergy Pontoise, France). Observed ratios of the two allele-specific transcript species were normalized against the average ratio obtained for a pool of genomic DNA samples. The relative abundance of the least abundant mRNA species is expressed as a percentage of the most abundant for untreated samples and this designation is maintained during analysis of puromycin-treated samples, even if the relative abundance exceeds 100%. For puromycin-treated samples, lymphoblastoid cells were incubated with 100 mg/ml of puromycin for 6 h before total RNA extraction. Each bar on the graph represents the mean of at least five independent measurements. Relative BRCA2 transcript abundance was assessed in 18 cell lines established from BRCA2-truncating mutation carriers, one from a carrier of a single amino-acid deletion and from eight wild-type BRCA2 individuals (combined and represented as a single bar). Samples were analysed by SimpleProbe s melting-curve analysis using the 5 0 UTR (203A/G) or N372H (z) probes, with the exception of two samples that were homozygous at both SNP positions (see Table 1 ). These were instead assayed using single-nucleotide primer extension (*).
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s on identical patient samples. Allele-specific BRCA2 transcript abundance for five truncating mutation carriers who were heterozygous at both the 5 0 UTR (203A/G) and N372H SNP positions was assessed with each probe by SimpleProbe s melting-curve analysis, as described in Figures 1 and 3 . a 1.4-3.3-fold reduction in the relative abundance of the least abundant transcript species. These results are similar to those reported in several other studies of endogenous transcripts targeted by NMD (Gismondi et al., 1998; Rodningen et al., 1999; Chatr-Aryamontri et al., 2004; Harries et al., 2004; Tournier et al., 2004) , including our own previous study of truncating mutations in the BRCA1 gene, for which we observed a 1.5-5-fold reduction in the amount of PTC þ transcripts (Perrin-Vidoz et al., 2002) .
Eight different PTCs located in exon 11, ranging in distance from 545 to 4527 nt upstream of the exon 11-12 boundary, were examined in this study. Additionally, we examined one mutation in exon 10, located 1080 nt upstream of the exon 10-11 junction. We determined that despite the large separation between the PTC and the nearest 3 0 exon-exon boundary, PTC þ transcripts from all these carriers were targeted by NMD, similarly to transcripts with PTCs located in smaller exons. Present models of NMD suggest that the association of several essential proteins with the postspliced mRNA is critical to trigger NMD. This trigger is believed to hinge on the interaction of critical protein components (hUpf2, hUpf3/Upf3X) bound to the EJC with a molecule (hUpf1) recruited to the post-termination complex deposited at the PTC (reviewed in Maquat, 2004) . The inability of the PTC located 559 nt upstream of the EEJ to elicit an NMD response in the TPI gene led to the speculation that if the distance between these factors is too great, the triggering of NMD may be compromised (Zhang et al., 1998) . However, transcripts of the b-globin and HSP70 genes harbouring PTCs 654 nt upstream and 678 and 1203 nt upstream of the nearest EEJ, respectively, are targeted by NMD (Maquat and Li, 2001; Neu-Yilik et al., 2001) . Moreover, we have reported that truncating mutations in the 3.4 kb exon 11 of BRCA1 ranging from 305 to 3395 nt upstream of the exon 11-12 boundary were also subjected to NMD (Perrin-Vidoz et al., 2002) . These studies combined with our current results demonstrate that NMD can function in very large exons and that the NMD resistance observed in the TPI study may represent an exception to the rule rather than the norm. Alternatively, it could represent an artefact resulting from the removal of several introns in order to create a large exon in the analysed minigene.
The biological mechanism(s) behind the variation in cancer risks for mutations occurring in the OCCR remain(s) unknown. However, an examination of the functional domains of BRCA2 does offer some possible insight. Despite its large size, the BRCA2 protein has very few recognized functional domains. There are eight small amino-acid repeats, the BRC repeats, located in its central region, which are known to interact with RAD51 (Mizuta et al., 1997; Wong et al., 1997; Chen et al., 1998) . This interaction can facilitate the formation and extension of RAD51 nucleoprotein filaments (Davies et al., 2001; Yang et al., 2005) , while three oligonucleotide-binding domains and a helical domain in the C-terminal tail are likely responsible for localizing BRCA2 to sites of DNA double-stand break repair via an interaction with single-stranded/double-stranded DNA junctions (Yang et al., 2002 (Yang et al., , 2005 .
The vast majority of germline BRCA2 mutations introduce PTCs. This has led to speculation that the variation in ovarian cancer risk associated with the OCCR may be attributable to differences in truncated BRCA2 protein expression (Thompson and Easton, 2001 ). According to this hypothesis, those mutations occurring 5 0 of the OCCR would encode for nonfunctional proteins possessing no known functional domains. Mutations in the OCCR would generate potentially dominant-negative truncated proteins containing some or all of the RAD51-binding BRC repeats but lacking critical functional regions in the C-terminus (e.g. DNA-binding domains). Finally, mutations 3 0 of the OCCR would generate BRCA2 proteins that could both bind RAD51 and may retain enough of the C-terminus to retain at least some normal functionality. This hypothesis, however, does not adequately address how truncating mutations occurring in the 5 0 -or 3 0 -end of the gene could lead to such similar phenotypes when their expected protein products differ so greatly. More importantly, this hypothesis does not take into account the role of NMD in ridding cells of PTC þ transcripts to prevent the production of truncated proteins.
When we began this study, we felt that the NMD mechanism itself represented an appealing alternative mechanism to explain the OCCR. The role of NMD in modulating the phenotype of several genetic diseases has been well established (reviewed in Holbrook et al., 2004) . Since the 3 0 boundary of the OCCR begins roughly 500 nt and extends some 4 kb upstream of the exon 11-12 boundary, there existed the possibility that PTC-introducing mutations in the OCCR differed from those elsewhere in BRCA2 by avoiding NMD. As a result, we expected that OCCR mutations might express stable mRNAs that could be translated into BRC repeat containing, dominant-negative, truncated proteins. However, we have demonstrated that PTC-introducing mutations throughout BRCA2 can trigger NMD, thus we have failed to identify any distinguishing characteristics of those transcripts with PTCs within the OCCR boundaries that could support a general role for NMD in the genotypephenotype variation observed among BRCA2 germline mutation carriers. This study is the first to experimentally test a hypothesis to explain the OCCR. Our results would indicate that alternative theories should be considered to explain this genotype-phenotype correlation.
